Welcome to our dedicated page for Walgreen Boots news (Ticker: WBA), a resource for investors and traders seeking the latest updates and insights on Walgreen Boots stock.
This page provides a focused view of news and announcements historically associated with Walgreens Boots Alliance, Inc. (formerly Nasdaq: WBA) and its related businesses, including Walgreens and Walgreens Specialty Pharmacy. Company communications highlight Walgreens as a U.S. retail pharmacy brand founded in 1901 that serves nearly 9 million customers and patients each day across approximately 8,500 stores in the U.S. and Puerto Rico, and Walgreens Boots Alliance as a pharmacy-led health and wellbeing enterprise formed through the combination of Walgreens and Alliance Boots.
News related to WBA and Walgreens has covered several key themes. One major area is corporate transactions and capital markets activity. In 2025, a series of announcements detailed the Agreement and Plan of Merger under which Blazing Star Merger Sub, Inc. merged with and into Walgreens Boots Alliance, Inc., resulting in the company becoming a wholly owned subsidiary of Blazing Star Parent, LLC, an affiliate of Sycamore Partners. Related releases described tender offers and consent solicitations for various series of Walgreens Boots Alliance and Walgreen Co. notes, pricing terms, extensions of expiration times and settlement dates, and the final results of these offers.
Another important news category involves the company’s transition from public to private ownership. A Form 8-K filed on August 28, 2025 describes the completion of the merger, the cash consideration and divested asset proceed rights received by shareholders, and the cessation of trading of WBA common stock and certain notes on Nasdaq. A subsequent Form 25 documents the removal of these securities from listing, and a Form 15 filed on September 8, 2025 terminates registration and suspends reporting obligations. Sycamore Partners separately announced the completion of its acquisition of Walgreens Boots Alliance, Inc. and its intention that Walgreens, The Boots Group, Shields Health Solutions, CareCentrix and VillageMD operate as standalone companies under private ownership.
Operational and healthcare-focused news also features prominently. Walgreens Specialty Pharmacy announced an expansion of its limited distribution drug network to 265 products, emphasizing its role in specialty medications for patients with rare, complex and chronic diseases and its independence from pharmacy benefit managers. Walgreens has also issued releases on vaccination services, including nationwide flu shot availability for individuals three years and older, walk-in and scheduled appointments, digital check-in features and incentives for myWalgreens members receiving vaccines.
Investors and observers using this news page can review historical coverage of WBA’s merger process, debt tender offers, governance and shareholder actions, as well as Walgreens’ specialty pharmacy initiatives and vaccination programs. For those tracking the evolution of the company, these articles collectively document WBA’s path from a publicly traded integrated healthcare and retail group to a privately held organization under Sycamore Partners, while also illustrating how Walgreens positions its pharmacies and specialty operations within the broader healthcare landscape.
Walgreens Boots Alliance (WBA) has appointed Bryan C. Hanson to its board of directors, effective October 27, 2022. With over 30 years in healthcare and technology, Hanson brings significant expertise to the company, serving on both the compensation and leadership performance committee and the finance and technology committee. Currently, he is the president and CEO of Zimmer Biomet. WBA's executive chairman, Stefano Pessina, and CEO Roz Brewer expressed optimism about his contribution to WBA's consumer-centric healthcare strategy.
Walgreens Boots Alliance (WBA) has declared a quarterly dividend of 48 cents per share, unchanged from the previous quarter and representing a 0.5% increase from the same quarter last year. The payment date is set for December 12, 2022, with record date November 15, 2022. This marks the company's 360th consecutive quarter of dividend payments and 47 years of raised dividends, showcasing its long-standing commitment to shareholder returns.
Walgreens Boots Alliance (WBA) announced that CEO Roz Brewer and CFO James Kehoe will present at the Credit Suisse 31st Annual Healthcare Conference on November 9, 2022, at 11:00 a.m. Pacific time in Rancho Palos Verdes, California. The presentation will be available via a live webcast on the WBA investor relations website. WBA, a leader in integrated healthcare and retail pharmacy, operates approximately 13,000 locations globally and is committed to improving health services and community well-being.
Walgreens has announced a significant update to its retail pharmacy operations, removing task-based metrics from performance reviews for its 24,000+ pharmacists. This initiative aims to enhance patient care and experiences by allowing pharmacists to focus on clinical services rather than administrative tasks. The company has invested over $190 million in fiscal year 2022 and plans an additional $265 million for fiscal year 2023 to support its pharmacies. These changes align with Walgreens' broader strategy to improve healthcare delivery and community engagement.
Walgreens launched the 2022-2023 Flu Index to track flu activity, showing it is over 10 times higher compared to last season and has doubled in the last two weeks. This initiative aims to encourage flu vaccinations amid rising flu cases across the United States. Notably, Louisiana, Texas, and Mississippi have reported the highest flu activity. The CDC recommends flu shots for everyone aged 6 months and older, especially before the holiday season.
Walgreens Boots Alliance (WBA) reported its fourth quarter and fiscal year results for 2022, highlighting a loss per share of $0.48, a decline from earnings of $0.41 in the prior year. Adjusted EPS fell by 31.8% to $0.80. Sales for the fourth quarter totaled $32.4 billion, down 5.3% year-over-year. Despite challenges, WBA raised its long-term U.S. Healthcare sales target to $11-$12 billion by fiscal year 2025, predicting low-teens adjusted EPS growth. The company's management expressed confidence in its strategic transformation towards becoming a consumer-centric healthcare leader.
Walgreens announces the availability of updated COVID-19 boosters, authorized by the FDA and recommended by the CDC, for individuals aged 5 and older at select locations. The boosters provide enhanced protection against COVID-19 variants, including Omicron BA.4 and BA.5. Parents are encouraged to schedule appointments for their children online or via the Walgreens app. With rising COVID-19 cases in the UK, Walgreens emphasizes vaccination as a critical preventive measure. The company has administered over 70 million COVID-19 vaccinations and is noted as the largest pediatric vaccine provider among retail pharmacies.
Walgreens Boots Alliance (WBA) has announced its plan to fully acquire CareCentrix for approximately $392 million, enhancing its presence in the $75 billion homecare sector. This acquisition follows WBA's previous 55% investment in CareCentrix in August 2022. The deal is expected to close by March 2023, subject to customary conditions. CareCentrix manages care for over 19 million members and generated pro forma sales of $1.5 billion in fiscal year 2021. The move aligns with WBA's strategy to transform into a consumer-centric healthcare company.
Walgreens has partnered with Lexie Hearing to offer Lexie Lumen hearing aids over-the-counter at Walgreens stores nationwide starting October 17. This initiative is a response to the OTC Hearing Aid Act, allowing consumers to buy hearing aids without a prescription. Priced at $799 or as low as $39 per month, the hearing aids come with a complete solution including batteries and a 45-day money-back guarantee. The collaboration aims to make affordable hearing aids more accessible to the approximately 37.5 million Americans with hearing difficulties.
Walgreens has announced its commitment as a founding sponsor of the Sustainable Medicines Partnership (SMP), aimed at promoting sustainable medicine practices over a four-year period. The SMP will focus on integrated projects to reduce waste and environmental impact, guided by six sustainability pillars. Walgreens has previously disposed of over 3 million pounds of unused medications through its safe disposal program. The partnership aligns with the United Nation’s Sustainable Development Goals and includes collaboration with various stakeholders to measure and optimize the carbon footprint of medicines.